A total of 73 patients with SARS-CoV-2 infection plus glucose levels between 140 and 400 mg/dl without assisted mechanical ventilation at hospitalization were randomly assigned to the 5 mg linagliptin daily + basal bolus insulin scheme (LI group, n = 35) or the basal bolus insulin scheme only (I group, n = 38) for the control of hyperglycemia. The gene discussed is INS; the disease is Hyperglycemia.